Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03630328 · ClinicalTrials.gov registry record · NA

Angelica Gigas Dietary Supplements and Human Immune Cells

A NA study of Innate Immune Cells, sponsored by Milton S. Hershey Medical Center.

Completed
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT03630328 is a NA study of Innate Immune Cells that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03630328, a NA study of Innate Immune Cells, has completed, sponsored by Milton S. Hershey Medical Center.

COMPLETED
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This human study will test the impact of dietary supplement vegicaps containing Korean Angelica root extract on 2 types of human immune cells: neutrophils that kill bacteria and other germs and natural killer (NK) cells that kill virus-infected cells and cancers. The investigators had done an earlier study with Korean Angelica supplement and discovered even a single dose of it increased blood neutrophils and NK cells within 24 h. In the new study, Korean Angelica capsules (Cogni.Q) will be compared head-to-head with dummy (placebo) capsules. This is to make sure the immune boosting actions are really from the Korean Angelica supplement.

Conditions Studied

Interventions

  • OTHER Placebo
  • DIETARY_SUPPLEMENT Cogni.Q

Study Locations (1)

Pennsylvania

  • Penn State College of Medicine - Hershey

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2019-02-06
Est. Completion 2026-02-25
Phase NA

Sponsor

Milton S. Hershey Medical Center

396 total trials

What the Registry Record Tells You About NCT03630328

The ClinicalTrials.gov registry entry for NCT03630328 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Innate Immune Cells appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03630328 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03630328 about?

NCT03630328 is a clinical study titled "Angelica Gigas Dietary Supplements and Human Immune Cells". This human study will test the impact of dietary supplement vegicaps containing Korean Angelica root extract on 2 types of human immune cells: neutrophils that kill bacteria and other germs and natural killer (NK) cells that kill virus-infected cells and cancers. The investigators had done an earlie...

What is the current status of trial NCT03630328?

This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2019-02-06. Estimated completion is 2026-02-25.

What conditions does trial NCT03630328 study?

This clinical trial studies the following conditions: Innate Immune Cells.

What interventions are being tested in trial NCT03630328?

The interventions under investigation include: Placebo (OTHER), Cogni.Q (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03630328?

This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03630328 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.